Browsing Tag
NASDAQ
804 posts
Bed Bath & Beyond (BBBY) to acquire Fathom (FTHM) in all-stock Everything Home expansion
$BBBY to acquire Fathom Holdings for $53.38M in all-stock deal expanding Marcus Lemonis's Everything Home strategy. Read the full executive analysis here.
Smith & Wesson Brands surges 20% as Q4 outperformance and a 22-point gap over NICS background checks recasts the firearms equity story
Smith & Wesson Brands ($SWBI) Q4 FY26 revenue jumps 26.7 per cent on 22-point NICS share gap. Full executive analysis on debt paydown and FY27 guidance here.
Why Robinhood is cutting 290 jobs even as trading activity reaches record levels
Robinhood’s decision to eliminate 10% of its workforce despite strong customer growth reveals a broader strategy to flatten management, accelerate product development and protect long-term operating leverage.
Columbus McKinnon doubles down on $70m synergy target and US demand resilience as post-Kito Crosby execution becomes the entire investment case
Columbus McKinnon ($CMCO) details $70M synergy target, $2.09B FY27 sales guidance, and 5.1x leverage path post-Kito Crosby deal. Full executive analysis here.
Meta slides as an AI executive exit and a hawkish Fed renew scrutiny of its AI strategy
Meta Platforms (META) slides as an AI executive exit and a hawkish Fed renew scrutiny of its AI strategy, even as its ad business stays strong. Full analysis.
Electronic Arts’ $55bn sale looks close, but Europe has added a second regulatory test
Electronic Arts’ $55 billion sale enters EU review as PIF, Silver Lake and Affinity face the July 22 test. Read what its deal spread signals for investors.
Could OpenAI and Anthropic push the next generation of smaller IPOs into SPAC mergers?
SPAC IPOs surge as SpaceX, OpenAI and Anthropic crowd Wall Street’s pipeline. Find out what the revival means for investors and private companies.
Biogen is paying up to $1bn for preclinical optionality. What does RayThera really add?
Biogen's $1 billion RayThera deal expands its immunology pipeline and raises fresh capital allocation questions. Read what BIIB investors should watch next.
Kardigan’s IPO demand looks strong, but the real test for KARD arrives in 2027
Kardigan raises $400 million in an upsized Nasdaq IPO to fund three cardiovascular trials. Discover the catalysts, cash runway and risks for KARD investors.
Innodata’s new CFO inherits a booming AI business and a valuation with little room for error
Innodata names Jayant Chauhan CFO as AI growth accelerates. See how finance discipline, M&A expertise and valuation pressure could shape its next phase now.